Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation

Cancer

Volumn 115, Issue 8, 2009, Pages 1598-1604

  Litton, Jennifer K ^a,b   Westin, Shannon N ^b   Ready, Kaylene ^b   Sun, Charlotte C ^b   Peterson, Susan K ^b   Meric Bernstam, Funda ^b   Gonzalez Angulo, Ana M ^b   Bodurka, Diane C ^b   Lu, Karen H ^b   Hortobagyi, Gabriel N ^b   Arun, Banu K ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

BRCA mutation; Breast cancer; Prophylactic mastectomy; Screening

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER SCREENING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; ONCOGENE; PATIENT ATTITUDE; PRIORITY JOURNAL; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

ATTITUDE TO HEALTH; BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC SCREENING; HEALTH SURVEYS; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; PERCEPTION; QUESTIONNAIRES; RISK REDUCTION BEHAVIOR;

EID: 65249182185     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24199     Document Type: Article

References (29)

1. Hall J, Lee M, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990; 250:1684-1689.
2. Easton D, Bishop D, Ford D, Crockford G. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993;52:678-701.
3. Wooster R, Neuhausen S, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to 13q12-13. Science. 1994;265:2088-2090.
4. Evans JP, Skrzynia C, Susswein L, Harlan M. Genetics and the young woman with breast cancer. Breast Dis. 2005- 2006;23:17-29.
5. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A. 1988;85:3044-3048.
6. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998;279:915-921.
7. Ford D, Easton D, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57:1457-1462.
8. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24:863-871.
9. Antoniou A, Pharoah P, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
10. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317-1325.
11. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328-2335.
12. Narod SA, Brunet J-S, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356:1876-1881.
13. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475-1479.
14. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multi- center, prospective study. J Clin Oncol. 2008;26:1331-1337.
15. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491-7496.
16. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22:1055-1062.
17. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633-1637.
18. King M-C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251-2256.
19. NCCN Clinical Practice Guidelines in Oncology: Genetic/ Familial High Risk Assessment: Breast and Ovarian. 2008; v. 1.2008. Available at: http://www.nccn.org
20. Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 1995;24:412-419.
21. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260-1268.
22. Ray J, Loescher L, Brewer M. Risk-reduction surgery decisions in high-risk women seen for genetic counseling. J Genet Courts. 2005;14:473-484.
23. Metcalfe K, Poll A, O'Connor A, et al. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet. 2007;72:208-217.
24. Kurian AW, Hartman A-R, Mills MA, Ford JM, Daniel BL, Plevritis SK. Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expect. 2005;8:221-233.
25. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89.
26. Geiger A, Nekhlyudov L, Herrinton L, et al. Quality of life after bilateral prophylactic mastectomy. Ann Surg Oncol. 2007;14:686-694.
27. Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24:1350-1356.
28. Tercyak KP, Peshkin BN, Brogan BM, et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol. 2007;25:285-291.
29. Bresser PJ, Seynaeve C, Van Gool AR, et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg. 2006; 117:1675-1682.